☆ 4.6 Article

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment

BMC CANCER (2016)

Journal

BMC CANCER

Volume 16, Issue -, Pages -

Publisher

BMC

DOI: 10.1186/s12885-016-2612-7

Keywords

Breast cancer; Vascular markers; sFLT1; PlGF

Funding

Department of Obstetrics and Gynecology of LMU Munich

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Background: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free survival, breast cancer-specific survival, and overall survival before the start of systemic treatment. Methods: A total of 200 patients' sera were included in this study, 100 patients being CTC positive and 100 patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A multi cytokine/chemokine array was used to screen the sera for the angiogenic markers. Results: Statistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore, significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to CTC negative and CTC positive patients. Conclusion: Both vascular markers showed enhanced expression in the CTC negative patient collective. To continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs. Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF values may potentially serve as predictive markers. Trial registration: The TRN of this study is NCT02181101 and the date of registration was the 4th of June 2014. The study was retrospectively registered.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus

Anna Maria Nuzzo, Domenica Giuffrida, Laura Moretti, Paola Re, Giorgio Grassi, Guido Menato, Alessandro Rolfo

Summary: This study compared the expression of anti-angiogenic sFlt1 and pro-angiogenic PlGF in placenta and maternal blood in GDM, GDM-PE, CTRL, and PE cases. The results showed higher sFlt1/PlGF values in GDM-PE maternal blood, decreased PlGF gene expression in GDM, PE, and GDM-PE placentae, and increased PlGF protein levels in GDM and GDM-PE placentae. Additionally, sFlt1 gene expression was higher in PE placentae, while sFlt1 protein expression was lower in GDM-PE placentae. These findings suggest a potential link between sFlt1 overproduction and PE onset in GDM pregnancies.

SCIENTIFIC REPORTS (2021)